News
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune, Inc. announces the European Patent Office intends to grant a patent for biodegradable polymeric nanoparticles designed to enhance therapeutic delivery in cancer therapies. The innovative platform aims to reduce side effects and improve therapy effectiveness -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive feedback from EMA on Phase 2 trial plans for TH104, a clinical candidate for pruritus in PBC, a rare liver disease -
